LEAH Labs
Rochester
About LEAH Labs
LEAH Labs provides Car T cells for curing B-cell lymphoma cancer in dogs. Scientists at LEAH Labs use precision gene editing to reprogram T immune cells with Chimeric Antigen Receptors (CAR) in order to create CAR T cells that seek out, specifically recognize, and destroy B cell lymphoma without the off-target side effects that come with chemotherapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $475.0K
- Funding stage: Seed
- Last round: Grant (May 2022)
- Website: leahlabs.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Product Research
Social Profiles
Canonical: https://fsome.com/organization/leah-labs-8968 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.